UniSuper Management Pty Ltd Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

UniSuper Management Pty Ltd lowered its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.7% during the 4th quarter, Holdings Channel reports. The firm owned 2,500 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. UniSuper Management Pty Ltd’s holdings in Alnylam Pharmaceuticals were worth $588,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Quantbot Technologies LP boosted its holdings in shares of Alnylam Pharmaceuticals by 1,754.5% in the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock worth $56,000 after buying an additional 193 shares during the last quarter. Bridgewater Associates LP purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $551,000. Captrust Financial Advisors grew its position in shares of Alnylam Pharmaceuticals by 34.4% during the 3rd quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock valued at $1,329,000 after acquiring an additional 1,237 shares during the period. True Wealth Design LLC increased its stake in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $4,539,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Citigroup upped their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Sanford C. Bernstein decreased their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $280.00 to $328.00 in a report on Monday, March 24th. Finally, Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $316.25.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 1,548 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,234 shares of company stock worth $19,958,097 in the last quarter. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $270.02 on Tuesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm’s fifty day moving average price is $260.34 and its 200-day moving average price is $260.58. The stock has a market cap of $35.13 billion, a P/E ratio of -124.43 and a beta of 0.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.